Skip to Accessibility Tools Skip to Content Skip to Footer

Cinqair® (reslizumab)

Cinqair (reslizumab) is indicated for the add-on maintenance treatment of patients over age 18 with eosinophilic asthma. It is prescribed for adults whose asthma is not controlled with their current asthma medicines. Cinqair helps prevent severe asthma attacks (exacerbations) and can improve your breathing.1,2

Approved in 2016 by the U.S. Food and Drug Administration (FDA), Cinqair is an add-on maintenance therapy. It can be given alone and in combination with other medications. It is not indicated for other eosinophilic conditions or for the relief of acute exacerbations, bronchospasms, or status asthmaticus.1,2

What are the ingredients in Cinqair?

The active ingredient in Cinqair is reslizumab.1,2

How does Cinqair work?

Cinqair is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa). It is thought to reduce the level blood eosinophils. It inhibits IL-5 signaling, resulting in a reduction of the production and survival of eosinophils. Eosinophils are a type of white blood cell that may cause the airways to swell and become narrow – contributing to the onset of asthma.1,2
Cinqair treatment may reduce severe exacerbations (flare-ups) and oral corticosteroid use. In clinical studies Cinqair has been demonstrated to improve patient quality of life through better lung function and fewer incidents of asthma attacks.1

What are possible side effects of Cinqair?

The most common side effect is sore throat pain. Talk to your healthcare provider or pharmacist for further information and a list of all possible side effects.1

If you experience breathing problems, paleness, flushing, swelling of the face, mouth, and tongue, itching, hives, or a skin rash, symptoms of low blood pressure-like fainting or dizziness, or have nausea or abdominal discomfort, seek medical help right away.

Serious allergic reactions, including anaphylaxis, can happen right after a Cinqair infusion. These reactions may not happen right away but can cause death. Your healthcare provider will observe your condition during and after a Cinqair infusion for any signs of a reaction.

Things to know about Cinqair

Cinqair should not be used to relieve sudden breathing problems. It should also not be used in those who have allergies to any ingredients in Cinqair.1,2

Before starting treatment with Cinqair, it is important to tell your healthcare provider about other medications, vitamins and supplements you are taking as well as any existing medical conditions, including but not limited to:1,2

  • Oral or inhaled corticoid steroid medicines
  • History of cancer
  • Parasitic (helminth) infections
  • Need for vaccinations. You should not receive a live vaccine while taking Cinqair.
  • Pregnancy or planning to become pregnant, or you are breastfeeding. It is not known if Cinqair may harm an unborn baby, or if it can pass into breast milk and harm your baby.

Teva Support Solutions® offers personalized education and support regarding Cinqair from a Clinical Nurse Educator by calling: 1-844-838-2211, Monday through Friday, 9 AM to 7 PM ET.2

Dosing information

Cinqair is administered via IV infusion by a healthcare professional in a medical setting. It comes in a 100 mg/10 mL single-use vial. The recommended dosage regimen is determined by your weight, 3 mg/kg once every 4 weeks delivered over 20-50 minutes. Infusion should be immediately discontinued if the patient experiences a severe systemic reaction, including anaphylaxis. 1

For more information, read the full prescribing information of Cinqair at https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf.

  1. Cinqair Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf. Accessed 4.11.19.
  2. Cinqair. Available at: https://www.cinqair.com. Accessed 4.11.19.